Arcutis Biotherapeutics, Inc. ARQT Debt - Unamortized Discount (Premium) and Issuance Costs, Net
Debt - Unamortized Discount (Premium) and Issuance Costs, Net at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredFinanceCostsNet.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s debt - unamortized discount (premium) and issuance costs, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s debt - unamortized discount (premium) and issuance costs, net?
- Arcutis Biotherapeutics, Inc. (ARQT) reported debt - unamortized discount (premium) and issuance costs, net of $798K in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s debt - unamortized discount (premium) and issuance costs, net changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s debt - unamortized discount (premium) and issuance costs, net decreased by 24.7% year-over-year, from $1.06M to $798K.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s debt - unamortized discount (premium) and issuance costs, net?
- Over 4 years (2021 to 2025), Arcutis Biotherapeutics, Inc.'s debt - unamortized discount (premium) and issuance costs, net has grown at a -24.4% compound annual growth rate (CAGR), from $2.65M to $865K.
- What does debt - unamortized discount (premium) and issuance costs, net mean?
- This represents the net adjustment to the face value of debt, accounting for original issue discounts, premiums, and capitalized debt issuance costs. These amounts are amortized over the life of the debt instrument to reflect the effective interest rate. It is essential for reconciling the carrying value of debt to its face value.